Sandoz reports 7% revenue growth in 2025, expands biosimilars and projects stronger 2026 outlook
Sandoz posts 7% revenue growth for 2025, driven by 15% biosimilars expansion, and guides for accelerated sales and margin growth in 2026.
Pharmaceuticals, Biotechnology and Life Sciences
Sandoz posts 7% revenue growth for 2025, driven by 15% biosimilars expansion, and guides for accelerated sales and margin growth in 2026.
Promatix Biosciences presents preclinical data on PBS293-MMAE, a first-in-class bispecific ADC targeting EGFR and EphA2 in colorectal cancer.
Novo Nordisk’s mid‑stage “triple G” obesity candidate UBT251 showed up to ~19.7 % mean weight loss in a Chinese phase 2…
Novo Nordisk reports up to 19.7% mean weight loss in Phase 2 trial of triple agonist UBT251, expanding its next-generation obesity pipeline.
Secarna to collaborate with Scenic to develop first-in-class disease-modifying oligonucleotide therapies for severe genetic diseases.
Genflow Biosciences, the only publicly listed longevity company in Europe, has launched a new development program in ophthalmology, focused on…
Valneva SE, a specialty vaccine company, and LimmaTech Biologics AG, a clinical-stage biotech company developing vaccines for the prevention of life-threatening diseases,…
Oncodesign Services has appointed Dr. Aidan Synnott as chief executive officer, to help strengthen its position as a trusted partner in drug discovery. The appointment reflects the company’s commitment to deepen client collaboration, enhance the quality of its science, and anticipate the evolving needs of the biopharma industry.
Evestia Clinical is kicking off with new identity of EMAS Pharma, as it sets its sights on rapid growth as a…
A UK biotech company Aelius Biotech whose unique laboratory gut model is used to trial new drugs and foodstuffs without the need for animal testing has raised a further £750,000 from the North East Venture Fund, supported by the European Regional Development Fund and managed by Mercia Ventures.